Product image of Ivabradin Krka (Ivabradine) supplied by GNH India

Ivabradin Krka

Active Ingredient:
Ivabradine
Origin:
EU

Ivabradin Krka (Ivabradine)

Ivabradine, the active ingredient in Ivabradin Krka, is an If channel inhibitor presented as an oral tablet for oral use. It is used to lower heart rate in patients with chronic stable angina and in heart failure with reduced ejection fraction. The medication is indicated for patients who require heart‑rate reduction without a decrease in myocardial contractility.

GNH India supplies Ivabradin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ivabradine acts on the cardiac pacemaker If current, making it useful in conditions where heart‑rate reduction improves symptoms and outcomes.

  • Chronic stable angina: reduces heart rate, improving myocardial oxygen balance and decreasing angina episodes.
  • Heart failure with reduced ejection fraction: lowers heart rate, contributing to improved ventricular filling and clinical outcomes.
  • Symptomatic tachycardia in angina patients: decreases excessive heart rate, helping relieve chest discomfort during activity.

How It Works

  • Ivabradine selectively binds to the funny (If) channels in the sinoatrial node, inhibiting the inward mixed sodium‑potassium current that drives spontaneous depolarisation. By reducing this pacemaker current, the drug slows the sinus rhythm without affecting myocardial contractility, atrioventricular conduction, or blood pressure. The effect is dose‑dependent and reversible upon discontinuation. The specificity for If channels allows heart‑rate control while preserving ventricular performance, making it distinct from beta‑blockers.

Side Effects

Ivabradine may be associated with several adverse reactions, which are categorised by frequency and severity.

Common Side Effects

  • Bradycardia: resting heart rate may fall below 50 beats/min.
  • Visual disturbances (phosphenes): transient luminous phenomena.
  • Headache: mild to moderate intensity.
  • Dizziness: especially on standing.
  • Fatigue: general feeling of tiredness.
  • Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects

  • Severe bradycardia: symptomatic, may require intervention.
  • Atrial fibrillation: new‑onset arrhythmia.
  • Symptomatic hypotension: marked blood pressure drop.
  • Visual loss: persistent visual impairment.
  • Allergic reactions: rash, angioedema, or anaphylaxis.

Precautions & Warnings

When prescribing Ivabradine, clinicians should consider several safety measures to minimise risk and ensure appropriate use.

  • Cardiac monitoring: assess baseline heart rate and ECG before initiation.
  • Concomitant beta‑blockers: avoid excessive heart‑rate reduction by adjusting doses.
  • Severe hepatic impairment: use with caution due to altered metabolism.
  • Pregnancy: safety not established; weigh potential benefits against risks.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Ivabradine can interact with other medicines that affect its metabolism or heart‑rate control, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce efficacy.
  • Other If‑channel inhibitors: additive bradycardic effect.

Moderate Interactions (Monitor Closely)

  • Calcium‑channel blockers (verapamil, diltiazem): may enhance bradycardia.
  • Digoxin: potential for increased arrhythmic risk.
  • Antihypertensive agents: monitor blood pressure and heart rate.

Frequently Asked Questions

Ivabradin Krka contains ivabradine, which is prescribed to lower heart rate in patients with chronic stable angina and in those with heart failure with reduced ejection fraction. By slowing the sinus rhythm, it helps relieve chest pain and improves cardiac efficiency in these conditions.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the electrical pathway that initiates each heartbeat. Inhibiting this current reduces the spontaneous depolarisation rate, leading to a slower heart rate while leaving contractility, blood pressure, and conduction largely unchanged.

The dosage of ivabradine is determined individually by the prescribing clinician based on the patient’s heart rate, clinical condition, and response to therapy. Healthcare professionals adjust the dose to achieve the desired heart‑rate reduction while monitoring safety.

Safety of ivabradine in pregnancy and lactation has not been established. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Ivabradin Krka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by directly inhibiting the If channel without affecting beta‑adrenergic receptors. This means it does not influence blood pressure or contractility, making it useful when beta‑blockers are contraindicated or insufficient alone.

Store Ivabradin Krka at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Ivabradin Krka is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Administration timing (e.g., with meals) follows the prescriber’s instructions to maintain consistent drug exposure.

The most serious adverse events include severe bradycardia, which can cause dizziness, syncope or require medical intervention, and atrial fibrillation, a potentially dangerous heart rhythm disturbance. Prompt medical evaluation is essential if these symptoms occur.

Ivabradin Krka should be avoided in patients with a resting heart rate below 50 beats/min, those with acute decompensated heart failure, severe hepatic impairment, or known hypersensitivity to ivabradine. It is also contraindicated when combined with other strong If‑channel inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ivabradine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT